MultiStem

Phase 2Small molecule

MultiStem is one of 7 small molecule programs targeting Systemic Inflammatory Response Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Inflammatory Response SyndromeRecruiting

ARDSTerminated

Systemic Inflammatory Response SyndromePhase 2

Recruiting

ARDSPreclinical

Terminated

Competition

Competitive Landscape

3 competitors in Systemic Inflammatory Response Syndrome

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Approved

1 3

MultiStem

HHealios K.K.

Phase 2

1 4

Januvia

ZZydus Therapeutics Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke2 trials

Study to Examine the Effects of MultiStem in Ischemic Stroke

Completed·HHealios K.K.·Phase 2·NCT01436487·134 enrolled

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

Terminated·HHealios K.K.·Phase 3·NCT03545607·206 enrolled

Myeloid Leukemia1 trial

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

Completed·HHealios K.K.·Phase 1·NCT00677859·36 enrolled

Liver Transplant1 trial

Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation

Terminated·PProf. Dr. Marc-H. Dahlke, Ph. D.·Phase 1·NCT01841632·3 enrolled

Systemic Inflammatory Response Syndrome1 trial

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Recruiting·HHealios K.K.·Phase 2·NCT04533464·156 enrolled

Acute Respiratory Distress Syndrome1 trial

A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

Completed·HHealios K.K.·Phase 1/2·NCT02611609·36 enrolled

1 more indication

ARDS1 trial

A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)

Terminated·HHealios K.K.·Preclinical·NCT04367077·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MultiStem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MultiStem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MultiStem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healios K.K. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHealios K.K.

MultiStem

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke2 trials

Myeloid Leukemia1 trial

Liver Transplant1 trial

Systemic Inflammatory Response Syndrome1 trial

Acute Respiratory Distress Syndrome1 trial

ARDS1 trial

References

Drug Info

Quick Facts

Related News